Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Hexal AG

Home Clinical Trial Sponsors and OrganizationsHexal AG

Hexal AG

ACTIVE

Germanywww.hexal.deSubsidiaryEstablished: 1986-01-01

Part of 诺华制药

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

111

96 active

Approvals

49

Total approvals

Agencies

5

Regulatory bodies

Founded

1986

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

59

53.1%

Phase 3

5

4.5%

Not Applicable

1

0.9%

Trial Status Distribution

Active, not recruiting

93

83.8%

Completed

13

11.7%

Not yet recruiting

3

2.7%

Recruiting

2

1.8%

Clinical Trials

Trials sponsored by this organization (111)

This is a comparative study of Nivolumab in participants with melanoma(skin cancer) requiring additional treatment with nivolumab.

Not yet recruiting

Mar 2026150 participants

Safety study of GME751 (Pembrolizumab Biosimilar) for Patients with Melanoma or Non-Small Cell Lung Cancer

Not yet recruiting

Oct 20251,038 participants

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants with Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Jan 2025720 participants

A study to compare efficacy, safety, and immunogenicity of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic non-squamous non-small cell lung cancer (NSCLC) (Jimmy-Lung)

Oct 202460 participants

Phase 3 study assessing the efficacy, safety and immunogenicity of SOK583A1 versus Eylea in patients with neovascular age related macular degeneration

Nov 2021460 participants

The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator

Active, not recruiting

May 2021460 participants

The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator

Active, not recruiting

Jan 2021460 participants

The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator

Active, not recruiting

Jan 2021460 participants

Page 1 of 14

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

13

Approvals

EMA

European Medicines Agency

7

Approvals

PHILIPPINES

Philippines FDA

7

Approvals

SFDA

Saudi Food and Drug Authority

20

Approvals

NPRA

National Pharmaceutical Regulatory Agency

2

Approvals

Recent Approvals

Fentanyl HEXAL MAT 50 mcg/h Transdermal Patch

Fentanyl HEXAL MAT 25 mcg/h Transdermal Patch

AMLOHOPE 10 mg/5 mg Capsule

AMLOHOPE 5 mg/10 mg Capsule

News

No news articles found

On this page

Overview
Clinical Trials111
Approvals49
News

Back to Organizations